Controversies in lung transplantation: Management of cytomegalovirus infections

Journal of Heart and Lung Transplantation

Volumn 21, Issue 8, 2002, Pages 841-849

  Zamora, Martin R ^a,b  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ANTIVIRUS AGENT; CIDOFOVIR; FOSCARNET; GANCICLOVIR; HYPERIMMUNE GLOBULIN; IMMUNOGLOBULIN; OKT 3; THYMOCYTE ANTIBODY; VALGANCICLOVIR;

BONE MARROW SUPPRESSION; BRONCHIOLITIS; COST EFFECTIVENESS ANALYSIS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DIAGNOSTIC ACCURACY; HUMAN; IMMUNE DEFICIENCY; INFECTION PREVENTION; INFECTION RISK; LUNG TRANSPLANTATION; MONOTHERAPY; PATHOGENESIS; PNEUMONIA; POLYMERASE CHAIN REACTION; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; RECIPIENT; REVIEW; RISK FACTOR; SURVIVAL TIME; TREATMENT OUTCOME; VIRUS DETECTION; VIRUS TRANSMISSION;

ANTIVIRAL AGENTS; BRONCHIOLITIS OBLITERANS; CYTOMEGALOVIRUS INFECTIONS; GANCICLOVIR; HUMANS; LUNG TRANSPLANTATION; POSTOPERATIVE COMPLICATIONS; RISK FACTORS;

EID: 0036347947     PISSN: 10532498     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1053-2498(02)00435-7     Document Type: Review

References (47)

1. Infection in organ-transplant recipients
2. Sequelae of cytomegalovirus pulmonary infections in lung allograft recipients
3. Infection in solid organ transplantation
4. The cost impact of cytomegalovirus disease in renal transplant recipients
5. Cytomegalovirus disease is associated with increased cost and hospital length of stay among orthotopic liver transplant recipients
6. The economic impact of cytomegalovirus infection after liver transplantation
7. Cytomegalovirus infections in heart and heart-lung transplant recipients
8. Lungs are a major organ site of cytomegalovirus latency and recurrence
9. Influence of anti-rejection therapy on the timing of cytomegalovirus disease and other infections in renal transplant recipients
10. Summary of the International Consensus Symposium on Advances in the Diagnosis, Treatment and Prophylaxis of Cytomegalovirus Infection
11. A comparison of ganciclovir and acyclovir to prevent cytomegalovirus after lung transplantation
12. Influence of donor and recipient HLA locus mismatching on development of obliterative bronchiolitis after lung transplantation
13. Cytomegalovirus infection and pneumonitis
14. Development of bronchiolitis obliterans syndrome in recipients of heart-lung transplantation - Early risk factors
15. Prevention and treatment of cytomegalovirus disease in thoracic organ transplant patients: Evidence for a beneficial effect of hyperimmune globulin
16. Use of the human cytomegalovirus (HCMV) antigenemia assay for diagnosis and monitoring of HCMV infections and detection of antiviral drug resistance in the immunocompromised
17. Detection of human cytomegalovirus antigenemia: A rapid diagnostic technique for predicting cytomegalovirus infection/pneumonitis in lung and heart transplant recipients
18. Detection of CMV pneumonitis after lung transplantation using PCR of DNA from bronchoalveolar lavage cells
19. Increased human cytomegalovirus (HCMV) DNA load in peripheral blood leukocytes after lung transplantation correlates with HCMV pneumonia
20. Comparison of PCR, antigenemia assay and rapid blood culture for detection and prevention of cytomegalovirus disease after lung transplantation
21. Evaluation of CMV viral load using TaqMan CMV quantitative PCR and comparison with CMV antigenemia in heart and lung transplant recipients
22. Evaluation of the Amplicor CMV, Cobas Amplicor CMV monitor, and antigenemia assay for cytomegalovirus disease
23. Failure of prophylactic ganciclovir to prevent cytomegalovirus disease in recipients of lung transplants
24. Impact of ganciclovir prophylaxis on heart-lung and lung transplant recipients
25. Ganciclovir prophylaxis for cytomegalovirus infections in pulmonary allograft recipients
26. Outcomes of lung transplantation using three different cytomegalovirus prophylactic regimens
27. Efficacy of a 6-week prophylactic ganciclovir regimen and the role of serial cytomegalovirus antibody testing in lung transplant recipients
28. Randomized trial of daily versus three-times-weekly prophylactic ganciclovir after lung and heart-lung transplantation
29. Quantification of cytomegalovirus (CMV) viral load by the hybrid capture assay allows for early detection of CMV disease in lung transplant recipients
30. Prophylaxis and management of cytomegalovirus pneumonitis after lung transplantation: A review of experience in one center
31. Use of cytomegalovirus hyperimmune globulin for the prevention of CMV disease in CMV seropositive lung transplant recipients
32. Cytomegalovirus immune globulin (CMVIG) in combination with ganciclovir provides cost-effective prophylaxis for CMV after lung transplantation
33. Comparison between CMV hyperimmune globulin and GCV for CMV prophylaxis in heart-lung and lung transplant recipients
34. Comparison of the efficacy and cost effectiveness of pre-emptive therapy as directed by CMV antigenemia and prophylaxis with ganciclovir in lung transplant recipients
35. Comparison of the efficacy and cost-effectiveness of pre-emptive therapy as directed by CMV antigenemia and prophylaxis with ganciclovir in lung transplant recipients
36. Combined antibody and ganciclovir treatment of murine cytomegalovirus-infected normals and immunocompromised BALB/c mice
37. Prevention and treatment of cytomegalovirus disease in heart transplant patients
38. Prevention of recurrent cytomegalovirus disease in renal and liver transplant recipients: Effect of oral ganciclovir
39. Maintenance therapy with oral ganciclovir after treatment of cytomegalovirus infection
40. Resistance of human cytomegalovirus to antiviral drugs
41. Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants
42. Evolution of mutations conferring multidrug resistance during prophylaxis and therapy of cytomegalovirus disease
43. Failure of ganciclovir treatment associated with selection of a ganciclovir-resistant cytomegalovirus strain in a lung transplant recipient
44. Ganciclovir resistance as a result of oral ganciclovir in a heart transplant recipient with multiple human cytomegalovirus strains in blood
45. Molecular analysis of human cytomegalovirus strains from two lung transplant recipients with the same donor
46. The impact of ganciclovir-resistant cytomegalovirus infection after lung transplantation
47. Use of CMV-IVIG with ganciclovir for the prevention of CMV disease in lung transplantation